[Hyperfractionated irradiation with simultaneous cisplatin chemotherapy in patients with far-advanced carcinoma of the head and neck].
From January 1988 to April 1989, 22 of 28 patients with advanced carcinomata of the head and neck have been treated by hyperfractionated radiotherapy (2 x 1.2 Gy/day, five days/week, total dose 74.4 to 79.2 Gy) and simultaneous application of Cisplatinum (20 mg/m2 day, i.v., five days in the first and fifth week of the radiotherapy). In 68% of the patients the treatment could be applied in full dose. All eight patients with primary application of a gastrostomy could be irradiated without split, whereas five of 14 patients without a gastrostomy had a split of greater than or equal to 2 weeks. The mucositis healed in all patients after the end of the irradiation. Up to now, no serious complications have been seen. One year cumulative locoregional control rate is 65%. This study serves as a pilot study for a randomized trial. According to the acute and subacute toxicity the applied treatment is feasible.
Glanzmann
C
C
Departement Medizinische Radiologie, Universitätspital Zürich, Schweiz.
Sartorelli
B
B
Thum
P
P
Lütolf
U M
UM
D002277:Carcinoma / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D002945:Cisplatin / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D006258:Head and Neck Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy*; D006801:Humans; D007262:Infusions, Intravenous; D011879:Radiotherapy Dosage; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction; D013997:Time Factors
D002945:Cisplatin
Hyperfraktionierte Bestrahlung und simultane Chemotherapie mit Cisplatin bei Patienten mit fortgeschrittenen Karzinomen der Kopf-Hals-Region.